Drag a card by its title · ⚙ to size, swap or remove

The company

Dyne Therapeutics, Inc.

DYN · Nasdaq

Health CareBiotechnologyNot moving yet

DYN stood above a rising 150-day average in 34 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 24.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 6
Industry in uptrend: 16% -15 in 4 wk
Insider buys, 12 months: $590K
Insider sales, 12 months: $337.2M
Officials’ trades on record: 0
Institutions holding: 235 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.

20 Apr – 19 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8

Sale orders, 12 months57

Buyers · sellers1 · 6

Who	Did	Shares	Traded
Brian S. PosnerDirector	bought	2,500at $16.00	2 Oct 2026filed 6 Oct 2026
John CoxCEO & President	sold	5,658at $18.88	8 Sep 2026filed 8 Sep 2026
Douglas KerrChief Medical Officer	sold	1,290at $18.88	8 Sep 2026filed 8 Sep 2026
Johanna Friedl-NadererChief Commercial Officer	sold	185at $18.88	8 Sep 2026filed 8 Sep 2026
Douglas KerrChief Medical Officer	sold	3,745at $24.35	4 Sep 2026filed 8 Sep 2026
Johanna Friedl-NadererChief Commercial Officer	sold	900at $24.35	4 Sep 2026filed 8 Sep 2026
Jason P. RhodesDirector	sold	1,359,674at $25.00	14 Aug 2026filed 17 Aug 2026
Jason P. RhodesDirector	sold	478,377at $25.00	14 Aug 2026filed 17 Aug 2026
Jason P. RhodesDirector	sold	322,465at $25.00	14 Aug 2026filed 17 Aug 2026
John CoxCEO & President	sold	4,986at $26.28	13 Aug 2026filed 17 Aug 2026
Jason P. RhodesDirector	sold	268,354at $26.20	13 Aug 2026filed 17 Aug 2026
Jason P. RhodesDirector	sold	94,415at $26.20	13 Aug 2026filed 17 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders235+16 on the quarter

New · exited46 · 30

Reported value$3.5B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	12,404,330$275.5M	+704,460+6.0%
Jupiter Topco LLCnew · filed 14 Aug 2026	11,997,738$266.6M	+11,997,738
FMR LLCadded · filed 13 Aug 2026	11,207,000$248.9M	+2,298,020+25.8%
STATE STREET CORPadded · filed 7 Aug 2026	7,458,263$165.6M	+804,517+12.1%
Orbis Allan Gray Ltdadded · filed 14 Aug 2026	7,006,542$155.6M	+244,311+3.6%
Atlas Venture Life Science Advisors, LLCreduced · filed 13 Aug 2026	6,800,099$151.0M	-2,330,366−25.5%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026	6,310,969$140.2M	-94,100−1.5%
TCG Crossover Management, LLCunchanged · filed 14 Aug 2026	4,615,144$102.5M	00.0%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026	4,048,428$89.9M	-113,613−2.7%
FCPM III SERVICES B.V.reduced · filed 14 Aug 2026	3,848,256$85.5M	-796,130−17.1%